Literature DB >> 16508724

Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment.

Tanri Shiozawa1, Ikuo Konishi.   

Abstract

The number of patients with endometrial carcinoma is markedly increasing in Japan. Therefore, understanding of its biological characteristics and establishment of appropriate treatment are important. In this article, we first describe the clinicopathology of the two types of endometrial carcinoma with their hormonal background and genetic alterations, and then discuss the pathways of early endometrial carcinogenesis. In addition, we also review the diagnostic and therapeutic modalities for early endometrial carcinomas with current controversies, especially regarding postoperative treatment strategies.

Entities:  

Mesh：

Year:  2006        PMID： 16508724     DOI： 10.1007/s10147-005-0546-1

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.850


  70 in total

1.  Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.

Authors:  T Kaku; H Yoshikawa; H Tsuda; A Sakamoto; M Fukunaga; Y Kuwabara; M Hataeg; S Kodama; K Kuzuya; S Sato; T Nishimura; M Hiura; H Nakano; T Iwasaka; K Miyazaki; T Kamura
Journal:  Cancer Lett       Date:  2001-06-10       Impact factor: 8.679

2.  PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma.

Authors:  R L Levine; C B Cargile; M S Blazes; B van Rees; R J Kurman; L H Ellenson
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

3.  Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability.

Authors:  J Palacios; L Catasús; G Moreno-Bueno; X Matias-Guiu; J Prat; C Gamallo
Journal:  Virchows Arch       Date:  2001-05       Impact factor: 4.064

4.  K-ras mutations in endometrial carcinomas with microsatellite instability.

Authors:  H Lagarda; L Catasus; R Arguelles; X Matias-Guiu; J Prat
Journal:  J Pathol       Date:  2001-02       Impact factor: 7.996

5.  Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer.

Authors:  T Ikeda; K Yoshinaga; A Suzuki; A Sakurada; H Ohmori; A Horii
Journal:  Oncol Rep       Date:  2000 May-Jun       Impact factor: 3.906

6.  Sentinel lymph node detection in patients with endometrial cancer.

Authors:  Hitoshi Niikura; Chikako Okamura; Hiroki Utsunomiya; Kosuke Yoshinaga; Junichi Akahira; Kiyoshi Ito; Nobuo Yaegashi
Journal:  Gynecol Oncol       Date:  2004-02       Impact factor: 5.482

7.  Involvement of cyclin-dependent kinase inhibitor p27Kip1 in growth inhibition of endometrium in the secretory phase and of hyperplastic endometrium treated with progesterone.

Authors:  T Shiozawa; T Nikaido; K Nakayama; X Lu; S Fujii
Journal:  Mol Hum Reprod       Date:  1998-09       Impact factor: 4.025

8.  Mutations of the Ki-ras oncogene in carcinoma of the endometrium.

Authors:  R F Caduff; C M Johnston; T S Frank
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

9.  Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.

Authors:  T Enomoto; M Fujita; M Inoue; J M Rice; R Nakajima; O Tanizawa; T Nomura
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962
View more
  7 in total

1.  Chemokines and Cancer Progression: A Qualitative Review on the Role of Stromal Cell-derived Factor 1-alpha and CXCR4 in Endometrial Cancer.

Authors:  Ashley S Felix; Robert Edwards; Robert Bowser; Faina Linkov
Journal:  Cancer Microenviron       Date:  2010-02-26

2.  Insulin in endometrial carcinoma chemotherapy: a beneficial addition and not a problem.

Authors:  Huilan Sha; Yanhui Li; Xuan Du; Hongbo Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

3.  Rictor is an independent prognostic factor for endometrial carcinoma.

Authors:  Shan-Yun Wen; Chang-Hua Li; Yan-Li Zhang; Yu-Hai Bian; Li Ma; Qiu-Lin Ge; Yin-Cheng Teng; Zhi-Gang Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

4.  ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.

Authors:  Israel Zighelboim; Amy P Schmidt; Feng Gao; Premal H Thaker; Matthew A Powell; Janet S Rader; Randall K Gibb; David G Mutch; Paul J Goodfellow
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

5.  Interferon‑stimulated gene 15 promotes progression of endometrial carcinoma and weakens antitumor immune response.

Authors:  Xiwa Zhao; Jingjing Wang; Yaojie Wang; Mengmeng Zhang; Wei Zhao; Hui Zhang; Lianmei Zhao
Journal:  Oncol Rep       Date:  2022-04-21       Impact factor: 4.136

6.  Network Pharmacology-Based Prediction of Active Ingredients and Potential Targets of ShengDiHuang Decoction for Treatment of Dysfunctional Uterine Bleeding.

Authors:  Hui Yang; Yu Fan; Jiangxue Cheng; Junbo Zou; Xiaofei Zhang; Yajun Shi; Dongyan Guo
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-11       Impact factor: 2.629

7.  CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.

Authors:  Kentaro Nakayama; Mohammed Tanjimur Rahman; Munmun Rahman; Kohei Nakamura; Masako Ishikawa; Hiroshi Katagiri; Emi Sato; Tomoka Ishibashi; Kouji Iida; Noriyuki Ishikawa; Satoru Kyo
Journal:  Int J Oncol       Date:  2015-11-26       Impact factor: 5.650
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.